Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EDNRA | P25101 | 20/20 | 0.72 |
| ▸ | EDNRB | P24530 | 19/20 | 0.72 |
| ▸ | ABCC3 | O15438 | 1/20 | 0.72 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.72 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.72 |
| ▸ | PDE4A | P27815 | 1/20 | 0.72 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Sitaxentan SCHEMBL803344 | 0.84 | EDNRA (1.00) | EDNRAEDNRBABCC3ABCC4ABCB11 | |
| Sitaxentan SCHEMBL29372653 | 0.84 | EDNRA (1.00) | EDNRAEDNRBABCC3ABCC4ABCB11 | |
| Sitaxentan SCHEMBL4142779 | 0.83 | EDNRA (0.98) | EDNRAEDNRBABCC3ABCC4ABCB11 | |
| Sitaxentan SCHEMBL12933796 | 0.83 | EDNRA (0.85) | EDNRAEDNRBABCC3ABCC4ABCB11 | |
| Sitaxentan Sodium SCHEMBL29357410 | 0.83 | EDNRA (0.69) | EDNRAEDNRBABCC3ABCC4ABCB11 | |
| SCHEMBL8555870 | 0.80 | EDNRA (0.64) | EDNRAEDNRBABCC3ABCC4ABCB11 | |
| Sitaxentan SCHEMBL12933822 | 0.79 | EDNRA (0.79) | EDNRAEDNRBABCC3ABCC4ABCB11 | |
| Sitaxentan SCHEMBL12933749 | 0.79 | EDNRA (0.90) | EDNRAEDNRBABCC3ABCC4ABCB11 | |
| Sitaxentan SCHEMBL12933800 | 0.79 | EDNRA (0.79) | EDNRAEDNRBABCC3ABCC4ABCB11 | |
| Sitaxentan SCHEMBL12933770 | 0.79 | EDNRA (0.90) | EDNRAEDNRBABCC3ABCC4ABCB11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9549926-B2 | Compositions and methods of treating pulmonary hypertension | GILEAD SCIENCES, INC. (US) | 2017-01-24 | — | — | US | disclosed |
| US-8980874-B2 | Method and composition for treating diabetic ketoacidosis | MIDWESTERN UNIVERSITY (US) | 2015-03-17 | — | — | US | disclosed |
| US-20140275098-A1 | COMPOSITIONS AND METHODS OF TREATING PULMONARY HYPERTENSION | GILEAD SCIENCES, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| US-20130225531-A1 | METHOD AND COMPOSITION FOR TREATING ALZHEIMER'S DISEASE AND DEMENTIAS OF VASCULAR ORIGIN | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2013-08-29 | — | — | US | disclosed |
| US-20120083447-A1 | Novel Therapeutic Treatments Using Centhaquin | MIDWESTERN UNIVERSITY (US) | 2012-04-05 | — | — | US | disclosed |
| US-20120070513-A1 | Method and Composition for Treating Diabetic Ketoacidosis | GULATI ANIL (US) | 2012-03-22 | — | — | US | disclosed |
| US-7973064-B2 | Administering to a mammal therapeutically effective amount of opiate analgesic and endothelin antagonist for therapy and prophylaxis of pain | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2011-07-05 | — | — | US | disclosed |
| US-20100311665-A1 | Method and Composition for Potentiating an Opiate Analgesic | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2010-12-09 | — | — | US | disclosed |
| US-20090263472-A1 | ENDOTHELIN RECEPTOR ANTAGONIST DERIVATIVES | NICOX S.A. (FR) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120083447-A1 | Novel Therapeutic Treatments Using Centhaquin | ADRB3, ADRA2A, ADRB2 | EDNRA 141/4885EDNRB 148/4885ABCC3 1702/4885 |
| US-20120070513-A1 | Method and Composition for Treating Diabetic Ketoacidosis | EDNRB, EGLN3, BDKRB2 | EDNRA 4/4885EDNRB 1/4885ABCC3 2893/4885 |
| US-20090263472-A1 | ENDOTHELIN RECEPTOR ANTAGONIST DERIVATIVES | EDNRA, EDNRB, ECE1 | EDNRA 1/4885EDNRB 2/4885ABCC3 1261/4885 |
| US-20140275098-A1 | COMPOSITIONS AND METHODS OF TREATING PULMONARY HYPERTENSION | PDE3A, PDE3B, PDE5A | EDNRA 18/4885EDNRB 12/4885ABCC3 2268/4885 |
| US-20130225531-A1 | METHOD AND COMPOSITION FOR TREATING ALZHEIMER'S DISEASE AND DEMENTIAS OF VASCULAR ORIGIN | PSEN1, PSEN2, CHAT | EDNRA 11/4885EDNRB 7/4885ABCC3 1440/4885 |
| US-20100311665-A1 | Method and Composition for Potentiating an Opiate Analgesic | OPRK1, OPRL1, OPRM1 | EDNRA 6/4885EDNRB 8/4885ABCC3 2300/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.